CASMI

Cancer drug funding decisions in Scotland: Impact of new end-of-life, orphan and ultra-orphan processes

CASMI_Brandmark_Positive

CASMI have recently published a new paper entitled Cancer drug funding decisions in Scotland: Impact of new end-of-life, orphan and ultra-orphan processes, in BMC Health Services Research. The paper was written by Dr Liz Morrell and Dr Richard Barker, in collaboration with co-authors from the Health Economics Research Centre and the Health Experiences Institute in [...]

September 18, 2017 Maeve Waite CASMI News 0

What else did the Cancer Drugs Fund do for us? Real-world data?

reformatted-slider-graphic-101 1

The Cancer Drugs Fund (CDF) in England – in its original incarnation between October 2010 and April 2016 – was a ring-fenced fund to provide access to cancer drugs not routinely funded by the NHS. Following reform during 2016, the CDF now offers a managed access option for cancer drugs [...]

September 4, 2017 Maeve Waite CASMI Views 0

Convergent evolution: cancer drug access in England and Scotland

reformatted-slider-graphic-101 1

The National Institute for Health and Care Excellence (NICE) in England, and the Scottish Medicines Consortium (SMC) in Scotland, face the same challenge of making drug funding recommendations that are fair to all users of the NHS and acceptable to society. Health technology appraisal is a devolved responsibility, so it [...]

August 21, 2017 Maeve Waite CASMI Views 0

NHS England and NICE changes to evaluation of drugs for rare conditions

reformatted-slider-graphic-101 1

In March this year, NICE’s board agreed a proposal to introduce Quality-Adjusted Life Years (QALYs) as the measure of value for Highly Specialised Technologies (HST – products to treat very rare conditions), with a limit of £100 000 per QALY, below which the treatment would automatically be funded.  In response [...]

June 20, 2017 Maeve Waite CASMI Views 0

Contrasting fortunes of immunotherapy drugs in first-line treatment of lung cancer

policy and impact_slider

The pharmaceutical press were quick to express their disappointment earlier this year at a draft decision by NICE, not to fund pembrolizumab (Keytruda: MSD) for first-line treatment of metastatic non-small cell lung cancer. The Appraisal committee concluded there was such uncertainty in the evidence base that it was impossible to [...]

May 22, 2017 Maeve Waite CASMI Views 0

What did the Cancer Drugs Fund do for us?

annonc_title800959362

Many of us woke last Friday morning to news coverage of the Cancer Drugs Fund, with reporting describing the Fund as “a waste of money” based on a paper published in Annals of Oncology by Aggarwal et al. The paper lays out a series of evaluations of the drugs provided [...]

May 9, 2017 Maeve Waite CASMI Views 0

Accelerating Access to Personalised Medicine

20170308-18

On March 8th 2017, the symposium, Accelerating Access to Personalised Medicine – a joint endeavour between CASMI, NIHR University College London Hospital Biomedical Research Centre, the Healthcare Values Partnership, and the UCL Personalised Medicines domain – was held at University College London. The main aims for this joint venture were [...]

May 8, 2017 Maeve Waite CASMI News 0

Does the Public Prefer Health Gain for Cancer Patients? A Systematic Review of Public Views on Cancer and its Characteristics

CASMI_Brandmark_Positive

CASMI have recently published a paper entitled Does the Public Prefer Health Gain for Cancer Patients? A Systematic Review of Public Views on Cancer and its Characteristics, in Pharmacoeconomics. The paper was written by Dr Liz Morrell and Dr Richard Barker, in collaboration with co-authors from the Health Economics Research Centre and the [...]

May 2, 2017 Maeve Waite CASMI News 0

CASMI at the RDM Symposium

RDMLogoJPG_Large_RGBBlacktype resized 2

CASMI will be attending the University of Oxford’s Radcliffe Department of Medicine Annual Symposium on Monday 6th March 2017. Held at the Saïd Business School in Oxford, our postdoctoral researcher, Dr Liz Morrell, will be presenting her academic poster on the comparison of the Cancer Drugs Fund and NICE decisions, [...]

February 27, 2017 Maeve Waite CASMI News 0

Funding of ultra-orphan drugs in Scotland and England

slider CASMI_graphic_10

Two years on from reforms to the Scottish Medicines Consortium’s processes for evaluation drugs for end-of-life and rare conditions implemented in 2014, Dr Brian Montgomery was asked by the Scottish Government to review their impact on access. The result was a wide-ranging report covering multiple aspects of drug access, with [...]

February 13, 2017 Maeve Waite CASMI Views 0